A Study of Inhaled Fexlamose for Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

2 1

What is this study about?

This study involves adults with Chronic Obstructive Pulmonary Disease, which is a long-term lung condition that makes breathing difficult and gets worse over time. The study focuses on people who have moderate to severe forms of this disease, meaning their lung function is significantly reduced. The treatment being tested is called Fexlamose, which is given as an inhalation solution that is breathed in through a special device called an eFlow Nebulizer. Some participants will receive Fexlamose while others will receive placebo. The purpose of the study is to evaluate how well Fexlamose works compared with placebo in treating this condition.

During the study, participants will continue taking their regular maintenance medications for their lung disease while also receiving either Fexlamose or placebo through inhalation. The treatment period lasts for 28 days, which is 4 weeks. Throughout this time, researchers will measure how well participants can breathe by checking their lung function, specifically looking at how much air they can force out of their lungs in one second. They will also use a computed tomography scan, which is a special type of imaging test that takes detailed pictures of the lungs, to see if there are any changes in the lung tissue. Additionally, participants will complete questionnaires about how their breathing problems affect their daily life and overall health.

The study will monitor participants for any side effects or health changes that might occur during treatment. This includes regular blood tests, urine tests, and measurements of oxygen levels in the blood. Doctors will also check the CT scans to look for any specific changes in the lungs that might be related to the treatment. The entire study is expected to last from early 2026 until the end of 2026, during which time participants will have several visits to the study site for assessments and monitoring.

1 Initial screening and lung function assessment

Your lung function will be tested through spirometry, a breathing test that measures how much air you can breathe out and how quickly. This test will be performed both before and after receiving a medication that opens your airways, called a bronchodilator.

The spirometry test will be repeated at multiple screening visits to ensure the measurements are consistent. Your baseline lung function measurement before the first dose must be similar to the measurements taken during screening.

A CT scan of your lungs will be performed to assess the extent of emphysema, which is damage to the air sacs in your lungs. The scan will measure whether less than 40% of your lung tissue shows emphysema.

Your current medications for chronic obstructive pulmonary disease must remain stable, with no changes in dosage for at least 4 weeks before this screening period and throughout the screening process.

2 Treatment assignment and baseline measurements

You will be randomly assigned to receive either Fexlamose inhalation solution or a placebo inhalation solution. A placebo is an inactive solution that looks identical to the study medication but contains no active ingredient.

Neither you nor the study staff will know which treatment you are receiving. This is called a double-blind study design.

Before starting treatment, baseline measurements will be taken, including lung function tests, oxygen levels in your blood measured by SpO2, and questionnaires about your respiratory symptoms and quality of life using the SGRQ-C questionnaire.

Blood and urine samples will be collected to assess your overall health through laboratory tests.

3 Treatment period with study medication

You will receive either Fexlamose or placebo as an inhalation solution. This means you will breathe the medication directly into your lungs using an inhaler device.

The treatment will continue for 4 weeks.

You will continue taking your regular maintenance medications for chronic obstructive pulmonary disease throughout the study period.

During this time, any side effects or health changes will be monitored and recorded.

4 Week 4 assessments

At the end of the 4-week treatment period, your lung function will be tested again using spirometry before taking your daily bronchodilator medication. The main measurement will be FEV1, which stands for forced expiratory volume in 1 second and measures how much air you can forcefully breathe out in one second.

Another lung function measurement called FVC, or forced vital capacity, will be taken. This measures the total amount of air you can forcefully breathe out after taking a deep breath.

A second CT scan of your lungs will be performed to measure changes in mucus plugging, which refers to mucus blocking your airways. This will be assessed using the MPSS score.

Your blood oxygen levels will be measured again using SpO2.

You will complete the SGRQ-C questionnaire again to assess any changes in your respiratory symptoms and quality of life.

Blood and urine samples will be collected for laboratory testing.

The CT scan will also be reviewed to check for any development of ground-glass opacities, which are hazy areas in the lungs that can be seen on imaging.

5 Safety monitoring throughout the study

Throughout the entire study period, any adverse events, meaning any unwanted or harmful effects, will be recorded and assessed.

Regular laboratory tests will monitor your blood cell counts, kidney and liver function, and urine composition to ensure the treatment is safe.

Any hospitalizations related to worsening of chronic obstructive pulmonary disease will be documented.

Who Can Join the Study?

You must be between 40 and 80 years old
You must have a confirmed diagnosis of COPD (a lung disease that makes it hard to breathe) related to cigarette smoking
You must be a current smoker or have smoked in the past, with at least 10 pack years of smoking (this means smoking one pack of cigarettes per day for 10 years, or an equivalent amount)
Your lung function test after using a breathing medication must show an FEV1/FVC ratio less than 0.70 (this is a measurement that shows how well air flows out of your lungs)
Your lung function before using breathing medication must be between 25% and 60% of what is considered normal, which indicates moderate to severe COPD
You must be able to perform breathing tests (called spirometry) correctly and consistently during screening visits
Your lung function measurements must remain stable between screening visits
A CT scan (a special X-ray picture of your lungs) must show that less than 40% of your lungs have emphysema (damage to the air sacs in the lungs)
You must have been using the same inhaler medications for your COPD without any dose changes for at least 4 weeks before joining the study
You must be using maintenance medications that include an inhaled bronchodilator (a medicine that helps open your airways to make breathing easier)
You must have had no more than 2 severe COPD flare-ups (called exacerbations) that required hospital admission in the past year

Who Cannot Join the Study?

The source data does not provide specific exclusion criteria, which are the reasons why someone cannot participate in this study
Without detailed information about who cannot join the study, it is not possible to list the specific medical conditions, medications, or other factors that would prevent participation
Generally, clinical trials have rules about who can and cannot participate to ensure the safety of participants and the accuracy of the study results
These rules typically cover things like other health problems, medications you are taking, or previous treatments you have received

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country
Diagnostics And Consultation Center Convex Ltd.	Sofia	Bulgaria
Medical Center Hera EOOD	Sofia	Bulgaria
Area Sanitaria De Ferrol	Ferrol	Spain
Hospital De Merida	Merida	Spain
Centrum Medycyny Oddechowej Mroz Sp. j.	Bialystok	Poland
Asclepius Medical Center OOD	Dupnitsa	Bulgaria
Medical Center Pulmo-2018 EOOD	Haskovo	Bulgaria
Complex Oncological Center – Shumen EOOD	Shumen	Bulgaria
Clinica Respira-Dr. Juanola	Mataró	Spain
Ostrowieckie Centrum Medyczne Anna Olech-Cudzik Krzysztof Cudzik s.c.	Ostrowiec Swietokrzyski	Poland
Msfmhat Cudxxv Pxyjke Cmqswe Eptm	Lovech	Bulgaria
Mkffdt Bigusel – Dziibmxkz	Wroclaw	Poland
Mtltamw Cyablf Maebuaexxa Pwqxzt Oxz	Pleven	Bulgaria

Trial status

Country	Status	Recruitment Start
Bulgaria	Not recruiting	27.02.2026
Poland	Not recruiting	27.02.2026
Spain	Not recruiting	27.02.2026

Trial locations

Investigated drugs:

6-THIO-ALFA-D-GLUCOPYRANOSYL 6-THIO-ALFA-D-GLUCOPYRANOSIDE

Fexlamose (AER 01) Inhalation Solution is an experimental medication being tested in this study. It is given as an inhalation solution, which means patients breathe it in through their lungs. This medication is being studied to see if it can help adults who have moderate to severe chronic obstructive pulmonary disease, a lung condition that makes breathing difficult. The study will look at whether this medication works better than placebo and whether it is safe for patients to use.

Placebo is an inactive treatment that looks like the real medication but contains no active medicine. It is used in this study to compare against the experimental medication to help researchers understand if the real medication is actually working.

Investigated diseases:

Chronic obstructive pulmonary disease

Chronic Obstructive Pulmonary Disease – Chronic Obstructive Pulmonary Disease is a long-term lung condition that makes it difficult to breathe. The disease develops gradually over many years, usually caused by smoking or long-term exposure to harmful particles and gases. The airways in the lungs become narrowed and damaged, and the air sacs lose their ability to stretch properly. As the disease progresses, people experience increasing shortness of breath, persistent cough, and frequent chest infections. The lungs produce excess mucus, which can block the airways and make breathing even harder. Physical activities become more challenging as the condition advances, and breathing difficulties may occur even during rest in later stages.

Trial ID:

2025-523020-50-00

Protocol code:

AER-01-002

NCT ID:

NCT06731959

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

A Study of Inhaled Fexlamose for Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?